|
CN112225793A
|
|
Lysosome targeting peptide, fusion protein thereof, adeno-associated virus vector carrying fusion protein coding sequence and application thereof
|
|
CN112226435A
|
|
Nucleotide sequence for reducing uricase gene expression and application thereof
|
|
CN111876432A
|
|
Acquisition and application of novel liver-targeted adeno-associated viruses
|
|
WO2021004446A1
|
|
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
CN111718947A
|
|
Adeno-associated virus vector for treating type IIIA or IIIB mucopolysaccharidosis and use thereof
|
|
WO2020108423A1
|
|
Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
|
|
CN109762056A
|
|
A kind of extracting method of nerve growth factor
|
|
US2021108197A1
|
|
Shrna expression cassette, polynucleotide sequence carrying same, and application thereof
|
|
CN109943554A
|
|
A method of extracting factor X activator from snake venom
|
|
CN109022377A
|
|
The ablation method of baculoviral in a kind of baculovirus expression system
|
|
CN108727486A
|
|
Long-acting nerve growth factor, preparation method and combinations thereof
|
|
CN107286233A
|
|
Low pain nerve growth factor mutant
|
|
CN107236041A
|
|
The antibody of IL 17
|
|
US2019105373A1
|
|
Nerve growth factor mutant
|
|
US2018161436A1
|
|
Nerve growth factor composition and powder injection
|
|
CN107708723A
|
|
Nerve growth factor composition and powder for injection
|
|
US2018104310A1
|
|
Nerve growth factor composition and powder injection
|
|
CN104887646A
|
|
Trospium chloride composition and preparation method thereof
|
|
CN104931598A
|
|
Method for determining content of nerve growth factor (NGF) in nerve growth factor preparation
|
|
CN104739808A
|
|
Trospium chloride double-release capsules and preparation method thereof
|
